Anthera reports topline data from BRIGHT-SC extension of blisibimod in IgA nephropathy Aug. 30, 2017 No Comments
Taiho Pharmaceutical begins enrolling patients in phase II study of TAC-302 Aug. 11, 2017 No Comments
FDA grants orphan drug designation for blisibimod as treatment of IgA nephropathy Aug. 10, 2017 No Comments